Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27821749 | 0.75 | COMT (0.35) | ALOX5AP | |
| SCHEMBL1939609 | 0.74 | CDK4 (0.43) | KDM4EMEN1KMT2AALOX5APALDH1A1 | |
| SCHEMBL28569989 | 0.72 | CYP2A6 (0.46) | KDM4EMEN1KMT2AALOX5APNPSR1 | |
| SCHEMBL27945168 | 0.71 | — | — | |
| SCHEMBL16675866 | 0.70 | HDAC6 (0.37) | MEN1KMT2AALOX5APCYP2C9HTR2A | |
| SCHEMBL827795 | 0.70 | OPRM1 (0.61) | MEN1KMT2ACYP2C9HTR2AALDH1A1 | |
| SCHEMBL13782273 | 0.70 | ALOX15 (0.33) | KDM4EKMT2AALDH1A1NPSR1 | |
| Ethane SCHEMBL27580685 | 0.68 | OPRM1 (0.54) | MEN1KMT2ACYP2C9ALDH1A1OPRM1 | |
| SCHEMBL30997796 | 0.68 | ALOX15 (0.32) | KDM4EKMT2ANPSR1 | |
| SCHEMBL6985863 | 0.68 | ALDH1A1 (0.46) | KDM4EMEN1KMT2AALOX5APALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | KDM4E 2761/4885MEN1 1564/4885KMT2A 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.